ARDX Ardelyx, Inc.
Ardelyx, Inc. (ARDX) is expected to report earnings on November 5, 2026, after the market close. The consensus earnings estimate is a loss of $0.02 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +0.3% since its last earnings release on August 6, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Ardelyx, Inc.
Ardelyx Inc is a clinical stage biopharmaceutical company. The Company engages in the discovery, development & commercialization of non-systemic, molecule therapeutics that work in the gastrointestinal tract to treat cardio-renal & metabolic diseases.
Sector
Healthcare
Industry
Drug Manufacturers/Other